Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine
- 5 January 2021
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 57 (1), 2003551
- https://doi.org/10.1183/13993003.03551-2020
Abstract
Prime time for a precision-based approach for treatment of idiopathic pulmonary fibrosis with an antioxidant, N-acetylcysteine https://bit.ly/30gl9vGFunding Information
- National Heart, Lung, and Blood Institute (K23 HL140199, UG3HL145266 and NIH/NHLBI R01HL1)
This publication has 15 references indexed in Scilit:
- Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet. Respiratory Medicine, 2016
- Randomized Trial of Acetylcysteine in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- Oxidative stress and pulmonary fibrosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2005
- Oxidative Stress in Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2002
- Antioxidative and Clinical Effects of High-doseN-Acetylcysteine in Fibrosing AlveolitisAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitisEuropean Respiratory Journal, 1995
- Extracellular Glutathione Suppresses Human Lung Fibroblast ProliferationAmerican Journal of Respiratory Cell and Molecular Biology, 1990
- Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis.JCI Insight, 1987